Ketamine vs. Spravato (Esketamine): Which Is Right for You?

If you've been researching ketamine therapy for depression or other mental health conditions, you've probably encountered two terms that seem similar but aren't quite the same: ketamine and Spravato (esketamine). The confusion is understandable—they're related medications with overlapping uses, but they differ in important ways that could significantly impact your treatment experience.

As someone who helps patients navigate these options every day, I want to give you a clear, honest comparison so you can have an informed conversation with your healthcare provider about which approach might serve you best.

Understanding the Science: Ketamine and Its Mirror Image

Let's start with the basics. Ketamine is a molecule that exists in two forms—think of them like your left and right hands. They're mirror images of each other, nearly identical but not interchangeable. Regular ketamine (sometimes called "racemic ketamine") contains both of these forms mixed together. Esketamine, marketed as Spravato, contains only the left-handed version of the molecule.

This might sound like a minor chemical distinction, but it has real implications. Research suggests that each form may interact slightly differently with brain receptors, potentially affecting both effectiveness and side effects. The racemic mixture has been used medically for over 50 years, while esketamine received FDA approval for treatment-resistant depression in 2019.

Some studies indicate that the combination of both forms in racemic ketamine may provide a more comprehensive therapeutic effect. However, esketamine's FDA approval means it has gone through the rigorous clinical trial process specifically for depression treatment. Both approaches have shown meaningful benefits for people struggling with depression that hasn't responded to traditional medications.

How Each Treatment Is Delivered

Perhaps the most significant practical difference between these treatments is how and where you receive them.

Spravato (Esketamine) is administered as a nasal spray, but here's the catch—you must receive it at a certified healthcare facility. After each treatment, you're required to remain at the clinic for at least two hours under observation. This is an FDA requirement, no exceptions. Treatments typically occur twice weekly for the first month, then weekly or biweekly thereafter.

Ketamine, when prescribed off-label for mental health conditions, offers more flexibility in delivery methods. It can be given intravenously (IV) at infusion clinics, intramuscularly at medical offices, or as sublingual tablets that dissolve under your tongue. This last option—sublingual ketamine—can be administered at home under appropriate medical supervision, offering privacy and convenience that many patients deeply value.

Comparing the Treatment Experience

The experience of receiving these treatments differs considerably, and these differences matter for real people living real lives:

• Time commitment: Spravato requires 2+ hours at a clinic for each session, plus travel time. At-home sublingual ketamine allows you to receive treatment in your own space, on your own schedule.
• Privacy: Some people feel uncomfortable receiving mental health treatment in clinical settings where they might encounter others. At-home treatment offers complete discretion.
• Comfort: There's something to be said for healing in a familiar environment. Many patients report that being in their own home, perhaps with soft lighting and comfortable surroundings, enhances their therapeutic experience.
• Accessibility: If you live far from a Spravato-certified center, have mobility challenges, or have a demanding schedule that makes clinic visits difficult, at-home ketamine may be more practical.
• Insurance: Spravato may be covered by insurance for treatment-resistant depression, though coverage varies and often requires prior authorization. Ketamine used off-label typically isn't covered, but this also means fewer bureaucratic hurdles.

What Does the Research Tell Us About Effectiveness?

Both ketamine and esketamine have demonstrated meaningful benefits for depression in clinical research. Studies indicate that approximately 50-70% of people with treatment-resistant depression experience significant improvement with either approach—a remarkable response rate for a population that, by definition, hasn't been helped by other treatments.

Some research suggests that racemic ketamine may produce slightly stronger antidepressant effects than esketamine alone, though head-to-head comparisons are limited. What we do know is that both can provide rapid relief—often within hours or days rather than the weeks required for traditional antidepressants to take effect.

For people in crisis, this speed can be life-changing. Many of my patients describe finally feeling hope again after their first few treatments, sometimes for the first time in years.

Making the Right Choice for Your Life

There's no universal "better" option between ketamine and Spravato. The right choice depends on your individual circumstances, preferences, and practical considerations.

Spravato might be worth exploring if you have insurance coverage for it and don't mind the clinic-based treatment model. It's FDA-approved specifically for treatment-resistant depression, which some patients find reassuring.

At-home ketamine therapy might be a better fit if you value privacy and discretion in your mental health care, want to receive treatment in the comfort of your own home, have a busy schedule that makes regular clinic visits challenging, live in an area without convenient access to Spravato centers, or prefer the flexibility of telemedicine-based care.

For patients in Florida and New Jersey, at-home ketamine therapy offers a way to access this treatment with minimal disruption to daily life. Through telemedicine consultations and medication delivered to your door, the entire process is designed around your comfort and convenience.

What Matters Most Is Taking the First Step

If you've been struggling with depression that hasn't responded to traditional treatments, I want you to know that there are options. Whether you ultimately choose ketamine, Spravato, or another approach entirely, what matters most is that you don't give up on finding relief.

The fact that you're researching these options tells me you're still fighting for yourself, and that takes courage. Depression lies to us—it tells us nothing will help, that we're beyond hope. But the evidence tells a different story. Thousands of people have found meaningful improvement through ketamine-based treatments after years of suffering.

You deserve to explore whether this might work for you too.

Ready to explore whether at-home ketamine therapy is right for you? Schedule a free consultation with Dr. Ben Soffer.